Core Points - Sichuan Shuangma announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. successfully passed an on-site inspection by the Russian Federal Ministry of Industry and Trade's drug inspection authority from July 30 to August 1, 2025 [2] - The company received the Good Manufacturing Practice (GMP) certificate from the Russian Federal Ministry of Industry and Trade, confirming compliance with the Eurasian Economic Union's pharmaceutical production standards [2]

Group 1 - Xinxiang Chemical Fiber will suspend production for approximately 90 days starting October 1, 2025, affecting an annual capacity of 31,200 tons, resulting in a revenue decrease of approximately 185 million yuan and a profit reduction of about 48 million yuan [1] - Bozhong Precision plans to transfer 18.29% of its stake in Suzhou Linghou Robot for 64 million yuan, retaining a 21.61% ownership post-transaction [1] - Haixing Electric is a recommended candidate for a State Grid procurement project, with an expected bid amount of approximately 128 million yuan [2] Group 2 - Samsung Medical is a recommended candidate for multiple State Grid procurement projects, with a total expected bid amount of approximately 193 million yuan [2][3] - Youxunda is a recommended candidate for a State Grid procurement project, with a bid amount of approximately 107 million yuan, representing 10.55% of its 2024 revenue [3] - Tiancheng Self-Control has received a notification for a seat assembly project from a well-known domestic new energy vehicle company, expected to start mass production in June 2026 [4] Group 3 - YKYY013 injection has received FDA approval for clinical trials to treat chronic hepatitis B virus infection [4] - Pulaide has signed a strategic cooperation agreement with an international electric tool brand, with a total procurement amount exceeding 700 million yuan over five years [4] - Sichuan Shuangma's subsidiary has obtained GMP certification from Russia, covering core aspects of drug quality and production systems [6] Group 4 - Boshi Co. has signed an industrial service contract worth approximately 96.99 million yuan with Guoneng Baotou Coal Chemical [7] - Wansheng Intelligent is a recommended candidate for a State Grid project, with an expected bid amount of approximately 67.98 million yuan, representing 7.25% of its 2024 revenue [9][10] - Huazi Industrial plans to sell its dairy farm assets for 38.5 million yuan, expecting a positive impact of approximately 11.7 million yuan on its current profits [10] Group 5 - Jinguang Electric has won a State Grid project with a total bid amount of approximately 28.4 million yuan, accounting for 3.82% of its 2024 revenue [11] - Nanjiao Food reported a net profit of 10,410 yuan for August, a year-on-year decrease of 98.31% [13] - Dongfang Bio's subsidiary has obtained registration certificates for two medical device products [15] Group 6 - Lanhua Kecai has signed a strategic cooperation agreement with Shanghai Pangu Power to promote intelligent and efficient transformation in the coal mining industry [17] - Yabao Pharmaceutical has decided to terminate the SY-009 research project, with a total investment of approximately 87.87 million yuan to be fully impaired [18] - Tian Shili's subsidiary has received approval for a new indication for its recombinant human urokinase injection for acute ischemic stroke treatment [20] Group 7 - Su Yan Jingshen's executives plan to increase their shareholding in the company, with a total investment of between 1.9 million and 2.66 million yuan [22] - Baiyun Electric and its subsidiary have won a State Grid project with a total bid amount of approximately 162 million yuan, covering multiple equipment types [23] - China West Electric's director has resigned due to work reasons, effective September 19, 2025 [25] Group 8 - Jianan Intelligent is a recommended candidate for a State Grid project with a total expected bid amount of approximately 73.12 million yuan [26] - Juhua Technology is a recommended candidate for a State Grid project with a total expected bid amount of approximately 142 million yuan [27] - Tengyuan Cobalt's actual controller has committed not to reduce holdings for the next 12 months, holding 37.89% of the total shares [28] Group 9 - Changfei Optical Fiber announced that Draka Comteq B.V. no longer holds H shares in the company after selling 37.59 million shares [28] - Mongcao Ecological's subsidiary has signed a contract for an ecological restoration project worth 225.2 million yuan [29] - Weiao Co. plans to distribute a cash dividend of 0.1 yuan per share, totaling approximately 39.29 million yuan [30]

Core Viewpoint - Sichuan Shuangma (000935.SZ) announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. successfully passed an on-site inspection by the Russian Federal Service for Surveillance in Healthcare, receiving the GMP certificate from the Eurasian Economic Union, which enhances its competitiveness in the active pharmaceutical ingredient market and supports the promotion of Teriparatide in the region [1] Group 1 - Hubei Jianxiang underwent an inspection from July 30 to August 1, 2025, by the Russian Federal Ministry of Industry and Trade's drug inspection agency [1] - The company received the GMP certificate, confirming compliance with the quality system for active pharmaceutical ingredient production recognized by Russia and the Eurasian Economic Union [1] - The certification validates the maturity of Hubei Jianxiang's production control, quality management, and public system assurance, strengthening its core competitiveness in the active pharmaceutical ingredient sector [1] Group 2 - The GMP certification provides essential qualification support for the market promotion of Teriparatide active pharmaceutical ingredients in the region [1] - This achievement is expected to enhance the company's influence in international markets and positively contribute to future operational performance growth [1]

Core Points - The company announced that its subsidiary, Hubei Jianxiang Biological Pharmaceutical Co., Ltd., successfully passed an on-site inspection conducted by the Russian Federal Service for Surveillance in Healthcare from July 30 to August 1, 2025 [1] - The company received the Good Manufacturing Practice (GMP) certificate issued by the Russian Federal Ministry of Industry and Trade, confirming compliance with the Eurasian Economic Union's pharmaceutical production standards [1]

Core Viewpoint - Sichuan Shuangma (000935.SZ) announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. successfully passed an on-site inspection by the Russian Federal Service for Surveillance in Healthcare, receiving the GMP certificate from the Ministry of Industry and Trade of the Russian Federation [1] Group 1 - The on-site inspection took place from July 30 to August 1, 2025 [1] - The successful acquisition of the GMP certificate confirms compliance with the Eurasian Economic Union's Good Manufacturing Practice standards [1]

Core Points - Sichuan Shuangma's subsidiary, Hubei Jianxiang Biopharmaceutical Co., Ltd., successfully passed an on-site inspection conducted by the Russian Federal Service for Surveillance in Healthcare from July 30 to August 1, 2025 [1] - The company received the "Good Manufacturing Practice Compliance Certificate" issued by the Russian Federal Ministry of Industry and Trade, confirming compliance with the Eurasian Economic Union's pharmaceutical production standards [1]

证券代码：000935 证券简称：四川双马 公告编号：2025-44 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 四川和谐双马股份有限公司（以下简称"公司"）控股子公司湖北健翔生物 制药有限公司（以下简称"湖北健翔"）于 2025 年 7 月 30 日至 2025 年 8 月 1 日接受了俄罗斯联邦工业和贸易部下属国家药品检查机构的现场检查。近日，公 司收到俄罗斯联邦工业和贸易部签发的《欧亚经济联盟药品良好生产规范符合性 证书》（以下简称"GMP 证书"），确认湖北健翔顺利通过该次检查。现将相 关情况公告如下： 一、本次 GMP 现场检查的相关情况 1、企业名称：湖北健翔生物制药有限公司 2、检查地址：湖北咸宁咸安经济开发区绿山路 9 号 4、检查范围：药品生产质量管理规范检查，范围涵盖药品质量体系、生产 体系、质量控制、人员管理、公用系统、厂房与设备等核心环节，产品涉及替尔 泊肽原料药。 四川和谐双马股份有限公司 关于控股子公司湖北健翔获得俄罗斯 GMP 证书的公告 3、检查报告编号：No 1565/50533/19-25 5、检查时间：2025 年 7 ...

Core Viewpoint - Sichuan Shuangma (000935) is actively advancing its strategic layout this year, focusing on market expansion, core product R&D innovation, and optimizing cost management across the entire chain [1] Group 1: Strategic Initiatives - The company is committed to deepening the exploration of potential market opportunities [1] - Emphasis is placed on refined management to enhance operational efficiency and overall management levels [1] Group 2: Performance Outlook - The company aims to deliver excellent performance to reward its investors [1] - Investors are encouraged to pay attention to the company's upcoming announcements regarding specific performance details [1]

Core Viewpoint - Sichuan Shuangma (000935) emphasizes its commitment to serving national strategies and the real economy, focusing on developing new productive forces and identifying high-growth potential industries and innovative sectors [1] Group 1 - The company is actively engaged in nurturing and cultivating several high-quality enterprises [1] - The goal is to create sustained value for shareholders [1]

证券日报网讯四川双马（000935）9月19日在互动平台回答投资者提问时表示，公司坚持稳健发展与精 细化管理，将继续夯实产业投资管理及私募股权投资基金管理业务，持续深化与基金投资者的沟通与互 动，提升服务质量，增强投资者对公司的信任和认可，实现公司长期稳定发展。 ...